Pharmacoeconomic evaluation of carfilzomib ixazomib for the treatment of relapsed and refractory multiple myeloma.

OBJECTIVE

This study assesses the cost-effectiveness of carfilzomib plus lenalidomide and dexamethasone (KRd) ixazomib plus lenalidomide and dexamethasone for relapsed and refractory multiple myeloma (RRMM) in China.

METHODS

A survival model was used to analyze health states and costs over a lifetime, with a 4-week cycle. Treatment effects on progression-free survival (PFS) and overall survival (OS) were modeled using hazard ratios (HRs) derived from the network meta-analysis (NMA). Health state utility values and disutility values for adverse events were obtained from published literature. Direct medical costs included drug costs, disease management costs, and costs associated with adverse event management. Costs and utilities were discounted by 5% annually. Both one-way and probabilistic sensitivity analyses were conducted.

RESULTS

The carfilzomib combination was found to be cost-effective, saving $127,513.22 per additional quality-adjusted life year (QALY) gained compared to the ixazomib combination. Sensitivity analysis showed that ixazomib's price, progression state utility, and carfilzomib's price significantly affected the results. At a $40,023.27 willingness-to-pay (WTP) threshold, the carfilzomib combination has a 100% probability of being cost-effective.

CONCLUSIONS

The study shows that, based on evidence from indirect comparisons, KRd is a cost-effective treatment option for RRMM patients in China.